When performance is behind plan, find out why before you make the next move.
EBITDA is below plan. A value-creation initiative has stalled. A recurring cost keeps returning. Or the last intervention produced less than expected.
The numbers tell you something is wrong. They don't necessarily tell you what's causing it.
The EBITDA Diagnostic traces financially significant problems across the organization to identify the execution conditions producing them, determine their economic consequence, and establish what needs to change for improvement to endure.
Before adding headcount, replacing leadership, buying another system, reorganizing the business, or committing more capital:
Make sure you're solving the right problem.
Execution Diligence for Private Equity
What Is Execution Diligence?
Every value creation plan contains assumptions about execution.
The organization must ship faster. Integrate technology. Improve margins. Professionalize operations. Increase engineering throughput. Reduce cost. Scale without creating equivalent complexity.
Execution Diligence asks: can this organization execute the value creation plan at the pace and economics the investment thesis requires?
The answer rarely exists inside one function. Execution constraints form between people, processes, technology, organizational structure, information flows, decision rights, product development, and day-to-day operations.
The EBITDA Diagnostic reconstructs those patterns, identifies the conditions producing them, and follows their consequences through to financial performance.
Execution Diligence connects how the company operates to what the investment ultimately earns.
The Execution Gap
The symptoms are usually visible before their causes are.
More headcount without proportional throughput.
Roadmaps that repeatedly slip.
Engineering capacity consumed by rework.
Manual workflows that survived the last three stages of growth.
Decisions requiring too many people and too much time.
Systems creating work instead of eliminating it.
Functions optimizing individually while execution deteriorates collectively.
Management may see each symptom independently. Execution Diligence determines whether they share an underlying cause — and what that cause costs every time it repeats.
The objective is not to find every inefficiency. It is to find the few systemic conditions producing material recurring economic consequences.
From Execution Finding to Financial Finding
Every material finding follows an attribution chain.
Structural Condition
↓
Recurring Behavior
↓
Operational Consequence
↓
Annual Financial Impact
↓
Cumulative Hold-Period Exposure
Where correcting the condition creates sustainable earnings improvement, the analysis continues:
EBITDA Improvement
↓
Exit Multiple
↓
Potential Enterprise-Value Impact
Definitions, formulas, assumptions, and financial inputs are established with the portfolio company's CFO. The result is not simply a list of organizational problems. It is a financially attributed view of where execution is consuming value, how frequently the cost recurs, how long it can continue, and what correcting it may mean for the investment.
The organization provides the evidence. The CFO validates the economics.
The Hold-Period Multiplier
A $10M annual execution inefficiency is not necessarily a $10M problem.
If the underlying condition remains in place, the cost can repeat every year it remains unresolved.
Year 1
$10M
cumulative
Year 2
$20M
cumulative
Year 3
$30M
cumulative
Year 4
$40M
cumulative
Year 5
$50M
cumulative
The underlying condition has not become five times larger. It has been allowed to repeat five times. That is the hold-period multiplier.
Finding the condition early creates more periods in which the recurrence can be interrupted. Finding the same condition late in the hold means much of the cumulative exposure has already occurred.
In a finite hold period, value has a clock.
The finding establishes the opportunity. Time determines how much of that opportunity remains recoverable.
The Economics of a Finding
Annual Recurring Impact
What the identified condition is costing the business each year if nothing changes.
Example: $10M annually
Cumulative Hold-Period Exposure
The cumulative economic exposure created if the recurring condition persists across the hold.
$10M annually × 5 years = $50M cumulative exposure
EBITDA Improvement
The portion of the identified opportunity that can translate into sustainable improvement in earnings once the underlying condition is corrected.
Example: $2M sustainable EBITDA improvement
Enterprise-Value Impact
Where an intervention produces sustainable EBITDA improvement, the improvement may receive an additional multiplier at exit.
$2M EBITDA improvement × 8× exit multiple = $16M potential enterprise-value impact
Cumulative hold-period exposure and enterprise-value impact represent different economic effects and are reported separately.
The first measures what continued recurrence can consume during the hold. The second measures what sustainable earnings improvement may contribute to enterprise value at exit.
Recurring inefficiency × time creates hold-period exposure. Sustainable EBITDA improvement × exit multiple can create enterprise value.
Cost of Inaction
Every quarter an unidentified structural condition remains in place creates another opportunity for the same behavior to repeat.
Another delayed decision.
Another unnecessary handoff.
Another rebuild.
Another manual workflow.
Another quarter of excess capacity.
Another roadmap commitment missed.
Another capital allocation decision made under the same conditions.
The cost accumulates quietly until someone traces the recurring consequences back to their source.
Annual recurring impact ($M)
What happens if this problem remains unresolved?
Year 1
$10M
cumulative exposure
Year 2
$20M
cumulative exposure
Year 3
$30M
cumulative exposure
Year 4
$40M
cumulative exposure
Year 5
$50M
cumulative exposure
The cost of waiting is not simply another year of inefficiency. It is one fewer year available to recover the value before exit.
The Diagnostic Surface
Organization and Accountability
Decision rights, ownership, spans and layers, incentives, role clarity, management overhead, information flow, and the relationship between authority and consequence.
Process and Workflow
Handoffs, approvals, rework, duplicated effort, manual processes, coordination overhead, decision latency, and recurring activity consuming capacity without proportional value.
Product and Engineering
Delivery capacity, prioritization, roadmap throughput, product operations, engineering workflows, technical dependencies, rework, and the ability to deliver at the pace the value creation plan requires.
Technology and Systems
Systems fragmentation, tooling, automation opportunities, unnecessary manual work, technical constraints, information architecture, and technology conditions creating recurring operating expense.
Leadership and Information
How information travels upward, whether ground-level reality reaches consequential decision makers, how decisions are actually made, and where organizational conditions prevent early intervention.
Financial Attribution
Recurring expense, capacity loss, cost of delay, EBITDA impact, cumulative hold-period exposure, recoverability, and potential enterprise-value impact.
Every dimension is evaluated against one question: is this condition increasing the organization's capacity to execute — or consuming it?
How Findings Are Produced
Stakeholder Interviews
Structured interviews across leadership and operating functions. The objective is triangulation, not consensus. The distance between what one organizational layer believes and another experiences is often where material findings begin.
Document and Artifact Review
Roadmaps, process documentation, financial assumptions, research, meeting artifacts, operating documentation, and historical evidence reveal patterns individual interviews cannot.
Direct Observation
Working sessions, planning meetings, reviews, and cross-functional interactions expose behavioral and operational conditions that never appear in a dashboard.
CFO Validation
Definitions, financial assumptions, formulas, and cost calculations are aligned with the portfolio company's CFO so material financial attributions can be tested against agreed economics.
Findings are synthesized across all four sources to reconstruct the organization as it actually executes — not simply as it reports.
The Output
What is happening?
The observable execution failure.
Why is it happening?
The structural condition producing it.
How often does it repeat?
The recurrence pattern establishing whether the problem is isolated or systemic.
What does it cost?
The CFO-validated annual financial impact.
What happens if nothing changes?
The cumulative exposure across the remaining hold period — and, where applicable, the potential effect on EBITDA and enterprise value.
Example Finding
Execution Constraint
Cross-functional product and engineering rework
Annual Recurring Impact
$10.0M
5-Year Cumulative Exposure
$50.0M
Recoverable EBITDA
$2.0M
Potential EV Impact @ 8×
$16.0M
Evidence Confidence
CFO-validated / triangulated across observation, artifacts, and stakeholder evidence
Commercial Structure
Fixed Diagnostic Fee
Each EBITDA Diagnostic begins with a defined scope and fixed fee covering the Execution Diligence engagement: evidence collection, direct observation, forensic analysis, financial attribution, CFO validation, and delivery of findings.
Scope and duration depend on organizational complexity, the breadth of the execution question, and the evidence required to establish credible attribution.
Fixed-fee engagements begin at $28,000.
Value Identification Fee
A 10% value identification fee applies to CFO-validated year-one recurring inefficiencies identified above the agreed threshold. The fee is calculated against the annual validated finding — not cumulative hold-period exposure and not potential enterprise-value impact.
$10M CFO-validated annual recurring inefficiency identified
→ $1M value identification fee
If that condition represents $50M of cumulative exposure across a five-year hold, the fee is not calculated against $50M.
We participate in the value identified once. The portfolio company retains the economics of every remaining period.
Engagement Scope
Focused Execution Diligence
For a known execution question, suspected constraint, or specific functional intersection where the Operating Partner needs a financially attributed answer before committing additional capital or intervention.
Comprehensive Execution Diligence
A cross-functional examination of execution capacity across the organization, designed to identify systemic constraints and prioritize them by annual financial impact and hold-period exposure.
Longitudinal Execution Diligence
Observation across multiple operating cycles for environments where behavioral patterns, leadership conditions, or recurring execution failures require time to become sufficiently visible and attributable.
The consultation determines the appropriate scope based on what the sponsor needs to know, the economic stakes, and the level of evidence required.
The Value of Finding It Earlier
The inefficiency has a run rate. The hold gives it time to repeat. Diligence determines when you see it. Intervention determines how much you recover. Exit determines what sustainable EBITDA improvement may ultimately be worth.
Execution Diligence Performed
The inefficiency has a run rate. The hold gives it time to repeat. Diligence determines when you see it.
Annual Recurring Impact ($M)
Year Execution Diligence Is Performed
Year 1
Cumulative Exposure — $50.0M Total
Exposure Already Incurred
$0
0 years at $10.0M annually — not recoverable
Addressable Hold-Period Value
$40.0M
4 years remaining × $10.0M annually
Sustainable EBITDA Improvement
$2.0M
20% of annual recurring impact
Potential Enterprise-Value Impact
$16.0M
$2.0M EBITDA improvement × 8× exit multiple
Cumulative hold-period exposure and enterprise-value impact are different economic effects reported separately. The first measures what continued recurrence can consume. The second measures what sustainable EBITDA improvement may contribute at exit.
Every Engagement Begins Here
Material execution constraints can exist long before they become visible in financial performance or board reporting.
Execution Diligence is designed to find them earlier, establish their source, quantify their recurring financial impact, and determine what continued inaction represents across the remaining hold.
The same problem discovered in Year 1 and Year 4 may have the same annual cost. It does not have the same investment consequence.
A conversation about what you are trying to see clearly, what is at stake, and what evidence would be required to answer it.